Praluent (Alirocumab) for Women 65 and Older: What Geriatric Transition to Adult Care Actually Means for You

What "Geriatric Transition to Adult Care" Means for a Woman on Praluent

Transition to adult care, in clinical shorthand, describes the structured process by which a patient moves from one care setting to another, most often from a pediatric subspecialty to adult medicine, but also from academic medical centers or intensive outpatient programs to community-based primary care. For a woman 65 or older, this phrase more often refers to handoffs between a hospital cardiology team, a lipid specialist, and a primary care or geriatric medicine provider. During any handoff, high-cost injectable drugs like alirocumab are frequently paused, deprescribed, or simply lost in the transition if no explicit plan exists.

Women 65 and older are not a uniform group. A 66-year-old in excellent cardiovascular health is clinically different from a 79-year-old managing polypharmacy and reduced renal clearance. Praluent's prescribing information does not restrict use by age, and the ODYSSEY OUTCOMES trial enrolled patients with recent acute coronary syndrome without upper age cutoffs, confirming benefit across subgroups including older adults.

Why This Handoff Is Riskier for Women Than Men

Women are diagnosed with cardiovascular disease an average of seven to ten years later than men, meaning many women reach their first cardiac event in their mid-60s to mid-70s, precisely when care transitions are most common. A 2021 analysis published in Circulation found that women with acute coronary syndrome were less likely than men to receive high-intensity statin therapy at discharge, and PCSK9 inhibitor initiation gaps are even wider. If a lipid specialist who initiated alirocumab retires or a hospital system changes formularies, a woman in this age group is at outsized risk of losing a drug that is actively reducing her cardiovascular risk.

The Postmenopausal Lipid Shift

Estrogen suppresses LDL production and raises HDL. When estrogen falls at menopause, LDL cholesterol rises by approximately 10 to 15 mg/dL on average and small dense LDL particles, which are more atherogenic, become more prevalent. This shift happens regardless of body weight. A woman who had acceptable LDL levels at age 50 may have significantly elevated levels by 60 without any change in diet. This biology is why PCSK9 inhibitors like alirocumab may carry particular value for postmenopausal women who cannot reach LDL targets on statins alone.

How Alirocumab Works and Why the Mechanism Matters at 65+

Alirocumab is a fully human monoclonal antibody that binds and inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Fewer PCSK9 molecules means more LDL receptors remain on the cell surface, pulling more LDL out of the bloodstream. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond what maximally tolerated statin therapy provides.

What the Numbers Look Like in Older Women

In the ODYSSEY OUTCOMES trial of 18,924 patients with recent acute coronary syndrome, alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events (MACE) by 15 percent compared to placebo over a median of 2.8 years. A pre-specified subgroup analysis showed consistent benefit in patients over 65. The trial did not publish sex-stratified subgroup data for the 65-plus cohort in the primary paper, which is an evidence gap worth naming. Women made up roughly 25 percent of enrolled participants, a proportion that under-represents the reality that women outlive men and accumulate more years of cardiovascular risk.

Pharmacokinetics: Does Age Change How the Drug Behaves?

Alirocumab is a large monoclonal antibody cleared by the reticuloendothelial system, not by the kidneys or liver cytochrome P450 enzymes. This matters for older women because:

• Renal impairment, common at 65+, does not meaningfully alter alirocumab exposure.
• Hepatic impairment has a modest effect on clearance but no dose adjustment is recommended for mild to moderate impairment per the current prescribing information.
• Body weight influences volume of distribution. Lower body weight (more common in older women) can produce slightly higher drug exposure, but no weight-based dosing is required.
• Drug-drug interactions are minimal because alirocumab does not use CYP enzymes. This is a practical advantage in a population managing multiple medications.

Dosing for Women 65 and Older

The starting dose is 75 mg subcutaneously every two weeks. If LDL remains above target after four to eight weeks, the dose is doubled to 150 mg every two weeks. For patients who prefer less frequent injections, 300 mg every four weeks is an FDA-approved alternative that delivers equivalent LDL lowering.

No dose reduction is required specifically because of age. The prescribing information states that no clinically meaningful differences in pharmacokinetics were observed based on age in the population pharmacokinetic analysis.

LDL Targets in Postmenopausal Women With ASCVD

The 2018 ACC/AHA Cholesterol Guideline recommends an LDL target of <70 mg/dL for very high-risk ASCVD patients and considers PCSK9 inhibitor therapy when LDL remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe. For women over 75, the guideline language notes that cardiovascular risk reduction from high-intensity statin therapy remains present but that the absolute benefit must be weighed against polypharmacy burden and patient goals, making shared decision-making especially important.

Managing the Transition: A Practical Checklist for Switching Providers

When a woman 65 or older moves her care to a new provider, alirocumab should not be automatically discontinued. A reasonable transition checklist includes:

1. Confirm the original indication (heterozygous FH vs. Clinical ASCVD vs. Off-label statin intolerance).
2. Pull a fasting lipid panel within 60 days of the care transfer.
3. Verify the current dose and injection schedule.
4. Review whether prior authorization from insurance is still active. PA approvals are often tied to the ordering provider, and a new prescriber may need to reauthorize.
5. Assess injection technique. Older women with arthritis or reduced grip strength may need device training or a caregiver assist.
6. Check for any new medications started during hospitalization that interact with statins (some antibiotics, antifungals) but note that alirocumab itself carries minimal drug interaction risk.

Female-Specific Conditions Alirocumab Touches

PCOS and Dyslipidemia in Younger Women Aging Into the 65-Plus Cohort

Women with polycystic ovary syndrome carry elevated LDL, triglycerides, and insulin resistance from their reproductive years. PCOS affects approximately 6 to 12 percent of women of reproductive age, and many of these women arrive at menopause already burdened by years of unfavorable lipid profiles and metabolic dysfunction. For this subgroup transitioning into the 65-plus category, alirocumab may be especially warranted because their cardiovascular risk trajectory started climbing decades earlier.

Familial Hypercholesterolemia: The Under-Diagnosed Condition in Older Women

Heterozygous familial hypercholesterolemia (HeFH) affects approximately 1 in 250 adults and is frequently under-diagnosed in women. Many women with HeFH are misattributed as having "diet-related" high cholesterol and under-treated for decades. By age 65, an undiagnosed woman with HeFH may have accumulated 40 years of excess LDL exposure. Alirocumab is FDA-approved specifically for HeFH, and a care transition is an appropriate moment to formally reassess whether this diagnosis applies.

Hypothyroidism and Statin Intolerance in Older Women

Hypothyroidism, which is far more common in women than men and increases in prevalence after menopause, can cause secondary hypercholesterolemia and also raises the risk of statin-associated myopathy. A woman who reports statin intolerance should have thyroid function assessed before alirocumab is started, because correcting hypothyroidism may substantially lower LDL without adding another drug. If statin intolerance is confirmed after thyroid optimization, alirocumab is a logical next step.

Osteoporosis and Cardiovascular Risk: The Shared Biology

Bone loss and vascular calcification share overlapping mechanistic pathways through OPG/RANK/RANKL signaling. Postmenopausal women lose bone and accumulate arterial plaque over similar timeframes, and low bone mineral density is associated with higher cardiovascular event rates. Alirocumab does not directly treat osteoporosis, but identifying a woman who needs both bone and cardiovascular protection is a reason to flag her for a comprehensive geriatric or women's health assessment at the point of care transition.

Pregnancy, Lactation, and Contraception

Alirocumab is contraindicated in pregnancy. This section applies primarily to women in the perimenopause window who are not yet confirmed to be postmenopausal and to women undergoing late reproductive transitions.

Pregnancy Safety Data

Animal reproduction studies with alirocumab showed no teratogenicity at doses up to 15 times the maximum recommended human dose. However, human data are limited to case reports. Because LDL cholesterol is a precursor for fetal adrenal steroid synthesis, marked LDL lowering during fetal development carries theoretical risk. For this reason, alirocumab should be discontinued if a woman discovers she is pregnant. Clinicians should not initiate alirocumab in a woman who is actively trying to conceive.

IgG antibodies cross the placenta, and alirocumab's half-life is approximately 17 to 20 days, meaning it remains detectable in maternal serum for weeks after the last injection. A woman planning pregnancy should discuss a washout window with her prescribing clinician. No formal washout duration is specified in labeling, but given the half-life, waiting at least 8 to 10 weeks after the last dose before conception attempts is a conservative and clinically reasonable approach.

Lactation Transfer

Alirocumab transfer into human breast milk has not been formally studied. IgG antibodies are present in breast milk at low concentrations, and oral bioavailability of a monoclonal antibody in a nursing infant is extremely low due to digestive proteolysis. The prescribing information advises caution and recommends weighing the benefits of breastfeeding against the potential risk. For most women over 65, lactation is not a clinical consideration, but for perimenopausal women in their early 50s who are late-career breastfeeders or who are nursing adopted infants, this conversation belongs in the pre-prescribing discussion.

Contraception Requirements

Alirocumab does not carry a mandatory contraception requirement the way teratogenic drugs like isotretinoin or methotrexate do. Still, because an unintended pregnancy would require immediate discontinuation and because the drug's long half-life means fetal exposure could occur before a positive test is recognized, women who are perimenopausal and not using reliable contraception should discuss this timing question explicitly with their provider.

Who This Drug Is Right For, and Who Should Pause Before Starting

The framework below was developed by the WomanRx editorial board to help women and their clinicians think through alirocumab candidacy at the 65-plus transition point. No published guideline organizes these considerations specifically for women in geriatric care transitions.

More likely to benefit from continuing or starting alirocumab:

• Postmenopausal women with confirmed clinical ASCVD (prior MI, stroke, peripheral artery disease) and LDL persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe
• Women with heterozygous familial hypercholesterolemia regardless of prior cardiovascular events
• Women with documented, verified statin intolerance across at least two different statins at low doses
• Women with PCOS who arrive at 65 with decades-long dyslipidemia and elevated residual cardiovascular risk

Worth a careful shared-decision conversation before continuing:

• Women 75 and older with no prior cardiovascular events and LDL moderately elevated (70 to 100 mg/dL) on statin monotherapy, where the absolute risk-benefit balance is less certain
• Women with severe frailty, limited life expectancy, or competing comorbidities where polypharmacy reduction is a higher priority than LDL optimization
• Women whose insurance prior authorization has lapsed and who face substantial out-of-pocket costs, since Praluent's list price exceeds $5,000 per year and affordability directly affects adherence

Not appropriate:

• Women who are pregnant or actively trying to conceive
• Women with no statin trial on record, where alirocumab is being considered as a first-line agent without documented statin intolerance or contraindication

Side Effects and Tolerability in Older Women

Alirocumab is generally well tolerated across age groups. The most common adverse effects in trials were injection-site reactions, occurring in approximately 7.2 percent of alirocumab-treated patients versus 5.1 percent on placebo. Nasopharyngitis, influenza, and urinary tract infections appeared at modestly higher rates in the alirocumab arm of ODYSSEY OUTCOMES, though the differences were small.

Neurocognitive Concerns: What the Data Say

Early theoretical concern arose that very low LDL levels achieved with PCSK9 inhibitors might impair neurocognitive function, since cholesterol is essential for myelin and synapse maintenance. A dedicated neurocognitive substudy of the FOURIER trial (evolocumab) found no significant difference in cognitive outcomes between the PCSK9 inhibitor and placebo groups over approximately two years. Alirocumab-specific neurocognitive data from ODYSSEY OUTCOMES similarly showed no excess cognitive events. For older women already concerned about dementia risk, this reassurance is clinically meaningful, though longer follow-up data would strengthen the conclusion.

Injection-Site Management in Women With Arthritis

Women over 65 have higher rates of osteoarthritis affecting the hands and wrists than men of the same age. Using the autoinjector pen rather than the prefilled syringe requires less fine motor force, and the 2 mL SureClick autoinjector approved for the 300 mg every-four-weeks dosing may be preferable for women who struggle with the every-two-weeks schedule mechanically. Rotating injection sites between the abdomen, upper arm, and thigh is required, and a physical or occupational therapy referral is appropriate if a patient cannot self-inject safely.

Monitoring After the Care Transition

Once alirocumab is continued with a new provider, monitoring is straightforward but requires intentionality:

• Lipid panel: Check at 4 to 8 weeks after any dose change, then every 6 to 12 months once stable.
• LFTs and CK: Not routinely required for alirocumab monitoring (unlike statins), but relevant if a patient remains on a statin concurrently.
• Injection-site review: Ask at each visit. Women who develop persistent erythema or induration may benefit from rotating to a different anatomical site or changing their injection technique.
• Insurance and adherence check: Prior authorization renewal cycles typically run 12 months. Missing a renewal is a common, preventable reason women stop alirocumab during care transitions.

The ACC/AHA 2018 guideline recommends reassessing the decision to continue PCSK9 inhibitor therapy after the first 12 weeks if LDL reduction is <30 percent from baseline, which may indicate injection technique errors, non-adherence, or rarely, anti-drug antibody formation.

The Evidence Gap: Where Women 65-Plus Are Under-Represented

Women made up only about 25 percent of ODYSSEY OUTCOMES participants. Older women, specifically those 75 and above, were even more sparsely represented. The 2022 ACC Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction acknowledges that evidence for PCSK9 inhibitor use in women is largely extrapolated from trials with male majorities. Sex-specific pharmacokinetic analyses exist in the prescribing label but are not powered for clinical guidance.

This is not a reason to withhold a drug that lowers MACE in a high-risk woman. It is a reason to frame the decision explicitly: the evidence is strong overall, less precise for women over 75, and the clinical conversation should include the patient's own values, her remaining cardiovascular risk burden, and her practical ability to self-administer injections reliably.